Compare H2O America (HTO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Tango Therapeutics Inc. — how do they compare? H2O America trades at $57.11 (market cap $2.45B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and H2O America pays a 3.01% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 39 Days and Tango Therapeutics Inc. for 0 Days on average.
| HTO | TNGX | |
|---|---|---|
Market Cap | $2.45B | $3.75B |
Volume | 419,336 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $65.43 | $32.90 |
52-Week Low | $44.44 | $7.50 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $4.24B | $2.77B |
Dividend Yield | 3.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.49, down 0.27% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with 12.91% net income margin and consistent earnings beats in recent quarters. Recent acquisitions in Texas expand operations but require significant capital investment. Cash flow trends improved from $10M in 2025 to $84M in 2026, supporting dividend sustainability.
Outlook remains positive with 83% analyst buy ratings and $66.50 consensus target offering 14% upside. Key risks include acquisition integration and execution challenges. The stock presents value for income investors given Dividend King status and strategic growth initiatives in regulated water utilities.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
